Background-Genome-wide association studies identified several single nucleotide polymorphisms (SNP) associated with prevalent coronary heart disease (CHD), but less is known of associations with incident CHD. The association of 13 published CHD SNPs was examined in 5 ancestry groups of 4 large US prospective cohorts. 
RNA in the INK locus [ANRIL])
, which may contribute to atherosclerosis through regulatory function on the CDKN2A-2B genes. 1 In addition to clinical CHD, variants in the 9p21 region (ie, rs10757274 and rs2383206) have shown to have associations with coronary artery calcification, 2,3 premature atherosclerosis, 2 ischemic stroke, 4 heart failure, 5 peripheral artery disease, 6 abdominal aortic aneurysm, and intracranial aneurysm 7 in white populations. Helgadottir et al reported early age of onset effects for CHD for this locus. 8 A recent meta-analysis of 22 studies including 35 872 cases and 95 837 controls, mostly white individuals, also suggested a larger effect (magnitude of association) of 9p21 variants in studies with earlier age of onset of clinical CHD. 9 Generalization of the genetic effects of this locus to populations of Asian ancestry was also observed in the latter meta-analysis.
A limited number of prospective studies of CHD have replicated the associations of the 9p21 region with incident CHD in white individuals, such as participants of the Atherosclerosis Risk in Communities (ARIC) study. 2 However, the associations did not replicate in studies of black individuals, including in the ARIC study participants 2, 10 ; although, it must be noted that the number of observations was suboptimal in several of these studies. 3 To our knowledge, a meta-analysis of the association of the 9p21 locus with incident CHD in other US minorities has not been performed. We also note that additional loci for CHD have been recently described [11] [12] [13] (CELSR2/PSRC1, MTHFD1L, MIA3 among others); these associations have not been replicated in US minorities.
The Population Architecture using Genomics and Epidemiology (PAGE) Study enables a comprehensive analysis of the association of previously validated CHD variants with incident CHD in data from multiple prospective cohort studies, and diverse cultural, ancestral, and socioeconomic settings. We examined whether CHD-related SNPs are associated with incident CHD in individuals of European ancestry in PAGE, and evaluated whether these SNPs are associated with incident CHD in US minorities, specifically in individuals self-identified as black, American Indian, Hispanic, and Asian/Pacific Islanders.
Methods

Population and Definition of CHD Events
The PAGE Study includes 4 large ongoing National Institutes of Health-funded population-based studies or consortia: Epidemiological Architecture for Genes Linked to Environment (EAGLE; based on 3 National Health and Nutrition Examination Surveys, 14 [NHANES]), the Multiethnic Cohort (MEC) study 15 , Women's Health Initiative (WHI) 16 , and Causal Variants Across the Life Course (CALiCo), a consortium of 5 cohort studies: Atherosclerosis Risk in Communities (ARIC), 17 Coronary Artery Risk in Young Adults (CARDIA), 18 Cardiovascular Health Study (CHS), 19 Hispanic Community Health Study/Study of Latinos (HCHS/SOL), and Strong Heart Study (SHS). 20, 21 This report is based on prospective data on incident CHD from the ARIC, CHS, SHS, and WHI studies. Fatal and nonfatal incident CHD events were defined as acute myocardial infarction (MI), fatal CHD, ECG diagnosis of MI (except in the WHI), and/or documented coronary revascularization procedures, based on record abstraction and confirmed by a panel of physician reviewers. Prevalent cases of CHD at the respective baseline visits were excluded.
The design of the parent studies has been previously described. Briefly, the ARIC study is a multicenter prospective investigation of atherosclerotic disease in a biracial population (white and black). 17 ARIC recruited 15 792 individuals age 45 to 64 years from 4 communities for a baseline examination in 1987 to 1989, with follow-up examinations in approximate 3-year intervals: during 1990 to 1992, 1993 to 1995, and 1996 to 1998. CHD events were ascertained from annual follow-up morbidity and mortality surveillance, including hospitalizations and deaths. Events were reviewed by 2 physicians, and differences were adjudicated. CHD events were defined as nonfatal acute (definitive or probable) MI, fatal CHD, and coronary revascularization procedures (coronary angioplasty or coronary artery bypass graft) through December 31, 2005. All subjects provided written informed consent. CHS is a population-based cohort study of risk factors for CHD and stroke in adults age Ն65 years conducted across 4 field centers in the United States. 19 The original, predominantly white cohort of 5201 persons was recruited in 1989 to 1990 from a random sample of people on Medicare eligibility lists; also, 687 black individuals were enrolled subsequently in 1991 to 1992 for a total sample of 5888 individuals. CHS participants completed standardized clinical examinations and questionnaires at study baseline and during 9 annual follow-up visits. Follow-up for clinical events occurred every 6 months. CHD was classified by the CHS end points committee; suspected events were investigated further by a physician review panel. CHD events were defined as nonfatal MI, coronary artery angioplasty, coronary bypass surgery, or cardiovascular disease (CVD) death caused by atherosclerotic CHD. CHD follow-up was available through June 30, 2007 . SHS recruited 4549 American Indian subjects age 45 to 74 years from 1989 to 1992 from 13 tribes at 3 study centers: Oklahoma, North and South Dakota, and Arizona. 20 Events were determined from medical records, autopsy reports, and informant interviews; all materials were independently reviewed by physician members of the SHS study's morbidity and mortality committees. CHD events were defined by the occurrence of nonfatal definite MI, definite CHD, ECG-evident definite MI, fatal definite MI, definite CHD, and sudden death. Follow-up went from 1989 to 1991 through December 31, 2006. The Indian Health Service Institutional Review Board and institutional review boards of the participating institutions and participating tribes approved the study; informed consent was obtained from all participants. WHI is a prospective cohort study investigating postmenopausal women's health in the US. 16 A total of 161 838 women age 50 to 79 years old were recruited from 40 US clinical centers between 1993 and 1998 to participate in the observational study and in clinical trials: postmenopausal hormone therapy (estrogen alone or estrogen plus progestin), a calcium and vitamin D supplement trial, and a dietary modification trial. 16 Study protocols and consent forms were approved by the institutional review boards at all participating institutions. Annual (observational studies) and semiannual (clinical trials) follow-up identifies selfreported events, which are then adjudicated following medical record review. 22 CHD was defined as acute (definitive or probable) MI requiring overnight hospitalization, fatal CHD, or coronary revascularization (coronary angioplasty or coronary artery bypass graft) procedures. Acute MI was determined according to standardized criteria that included cardiac pain, cardiac enzyme (and troponin levels), and ECG readings. Events as of August 2009 are included in these analyses. A subset of 21 000 WHI women was selected for genotyping and for inclusion in the current study. Women were selected based on self-reported history of disease, incident event outcomes, DNA availability and consent, and racial/ethnic diversity. 
SNP Selection and Genotyping
SNPs (in genes or regions) were identified from published GWAS for their association with CHD, and those available as per January 2009 were genotyped in PAGE studies. [23] [24] [25] [26] [27] [28] SNPs were available in at least 1 study for the following loci: the 9p21 region near the
, and PCSK9 (rs11206510). We examined the correlation among SNPs in the same region using pair-wise r 2 and DЈ statistics 29 for linkage disequilibrium (LD). For 3 SNPs located in the 9p21 region (rs10757278, rs1333049, rs2383207) in black subjects (ARIC) and in American Indian subjects (SHS), the correlation among SNPs was 0.85 or more in blacks and in American Indians (online-only Data supplement Figure S1A -D, http://stroke.ahajournals.org). Therefore, we only reported associations for 1 SNP in the region (rs10757278). For the 2 APOE SNPs, correlation was 0.99 in all ethnicities, and therefore we reported only associations for rs429358.
Genotyping was performed in 2 centers: the CALiCo Core Genotyping Laboratory at Human Genetics Center at The University of Texas (Houston, TX) genotyped samples from ARIC, CHS, and SHS using Taqman assays (Applied Biosystems); the Translational Genomics Research Institute (Phoenix, AZ) genotyped WHI samples using Illumina's Veracode GoldenGate genotyping assays. Each laboratory genotyped 360 HapMap samples for cross-laboratory and cross-platform quality control. Quality control assessments included sample call rates (Ͼ95%), concordance of blinded replicates (Ͼ98%), and deviation from Hardy-Weinberg equilibrium among controls within self-reported ethnic group (PϽ0.01). In CALiCo populations with previous GWAS characterization (ARIC and CHS), genotyped SNPs were used (Affymetrix 6.0 for ARIC and Illumina Human 370CNV BeadChip) in CHS. 30 Quality control for GWAS has been described. 30 All alleles were aligned to positive strands.
Statistical Analysis
All analyses were stratified by study and self-reported ethnicity. Cox proportional hazard models (implemented in SAS 9.2 using PROC PHREG procedure or in R) 31 were used to estimate ethnic-specific associations of SNPs with CHD (hazard ratios [HR] and 95% confidence intervals) while adjusting for baseline levels of covariates age and sex, study site (as applicable) and population stratification. We also performed an analysis adjusting for body mass index, ever smoking, type 2 diabetes, systolic blood pressure, blood pressurelowering medication use and education (12 years or equivalent versus Ͻ12 years). Results were unchanged in fully adjusted models and therefore we report minimally adjusted models except for 9p21 region in white subjects. Lipid measures were only available in a subset of women in the WHI and therefore were not included in analyses. To explore phenotypic heterogeneity as described by Kitsios et al, 32 we also performed sensitivity analyses using an alternative CHD definition that included only fatal CHD and nonfatal MI.
PAGE studies used the following strategies to adjust for population stratification: ARIC white individuals and WHI used principal components estimated from preexisting GWAS data, adjusting only for PCs significantly associated with the outcome (␣ϭ0.05). For ARIC black individuals, a set of 1536 ancestry informative markers genotyped among 3965 black ARIC participants was used to derive mean percentage of European ancestry using the software ANCESTRYMAP. 33 This variable was included as a covariate in the regression analyses. SHS used self-reported percentage of Indian blood.
All analyses used additive genetic models as described in the initial publications for these SNPs and/or the replication studies in white participants. WHI used weighted analyses to account for the sampling schema, with sample weights ranging from 1 to 60.4. The study-specific log (HR) estimates were combined within each ethnicity using inverseweighted variance meta-analyses. 34 Summary estimates and 95% CI are reported. A nominal replication was considered a probability value Ͻ0.05 and a Bonferroni adjusted replication was considered probability value Ͻ0.0008 (13 SNPs and 5 ethnicities for ␣ϭ0.05).We also tested for evidence of between-study heterogeneity 35 by estimating the between-study variance and the I 2 metric, which is a measure of the percentage of the total variation across studies caused by heterogeneity rather than chance. 36 For the 9p21 SNP association, which showed significant between-study heterogeneity (PϽ0.10), we performed stratified analyses by age and sex.
We also constructed an additive genetic risk score (0 -18 alleles) comprising the number of risk alleles at the 9 loci showing significant replication in white individuals (PϽ0.0008); we used data from the following SNPs (coded allele): rs10757278 (G), rs2549513 (A), rs499818 (A), rs6922269 (A), rs429358 (C), rs4804611 (A), rs501120 (T), rs268 (G), and rs2943634 (C). We then tested the association of categories or continuous risk scores with incident CHD in WHI, the study that had data on all the SNPs.
For associations in samples of US minorities, we estimated power assuming an additive genetic effect, magnitude of effect estimate of reported associations in white individuals, an ␣ϭ0.05, a 2-sided test, and population baseline prevalence of 0.10 (Quanto v.1.2.4).
Results
Associations with incident CHD events were examined in the prospective cohorts of white individuals (up to 26 617 individuals and 6626 events), black individuals (8018 individuals and 914 events), Hispanic individuals (1903 individuals and 113 events), American Indian individuals (3669 individuals and 595 events) and Asian/Pacific Islander individuals (885 individuals and 66 events). The mean follow-up of studies varied from 9.1 to 15.7 person-years (online-only Data Supplement Table I ). CHS participants were older than were individuals in other studies, and WHI recruited only women (Table 1) . CHD risk factors varied across studies and ethnicities.
We first evaluated replication of SNP associations with incident CHD in samples of white individuals. Nine of 13 investigated loci associations showed replication by our a priori criteria (PϽ0.0008) including the 9p21 region ( Table 3 ). Metaanalyses including incident findings from published variants in the ARIC study are shown in online-only Data Supplement Table II . Replicated loci had similar direction and magnitude of effects as reported. Using an additive genetic score from these 9 SNPs, we observed an increased hazard of CHD across increasing categories of genetic risk score (Table 4) . CELSR2/SORT, MIA3, and SMAD3 SNPs were not associated with incident events in white individuals.
In the 9p21 region, the proxy SNP rs10757278 had associations of similar direction and magnitude as in published studies, but we noted significant between-study heterogeneity at this locus (Table 2) . Each copy of the rs10757278 G allele was associated with increased hazard of CHD that varied from 10% (CHS) to 22% (WHI; P for heterogeneityϭ0.03; I 2 ϭ71.5%). Study-specific cumulative incidence findings by genotypes are shown in online-only Data Supplement Table III . Estimates were unchanged in analyses adjusted for multiple CHD risk factors (Table 2) . Sex-specificity and the varying age at recruitment were investigated as possible sources of the heterogeneity of effects. The hazard ratios for CHD by decade of age at study recruitment summarized in Figure A show a notably greater risk of CHD for individuals age 55 years or younger. The magnitude of the risk estimates decreased with increasing decade of age, although large heterogeneity remained across age strata ( Figure  1A , online-only Data Supplement Table IV ). In sex-specific analysis, the CHD hazard was greater in women compared with in men, with large between-sex heterogeneity of effects ( Figure  1B ; online-only Data Supplement Table V) . In analyses stratified by age and sex, the risk of CHD was greater in women than in men at earlier ages ( Figure 1C ; online-only Data Supplement Table VI ). To investigate CHD phenotypic heterogeneity caused by inclusion of revascularization procedures, we performed sensitivity analyses using only nonfatal MI and CHD fatal events. Between-study heterogeneity for the CHD associations of rs10757278 was no longer present in these analyses (Table 2) . Online-only Data Supplement Table VII, shows the findings using this definition for additional loci showing heterogeneity. We also examined whether SNP associations with CHD generalize to samples of US minority groups (Table 5) . Because of high correlation between the SNPs in the 9p21 region in black individuals and SHS American Indian participants (online-only Data Supplement Figure S1A -D, http://stroke.ahajournals.org), we only report findings for rs10757278. The association of rs10757278 with incident CHD did not replicate in black participants despite large sample sizes and greater than 80% power to detect an Table 1 ) and population stratification. §Meta-analyses using fixed effect models. effect of similar magnitude to white individuals (Table 5) . SNPs in the 9p21 region were nominally associated with CHD in American Indian individuals with similar magnitude and direction of effect as in white individuals. However, we also observed significant between-study heterogeneity of effect across the 4 groups of American Indian participants, as well as in analyses including only SHS participants (Table 5) . We were unable to evaluate the associations in the 9p21 region in Hispanic and Asian/Pacific Islander participants because of limited sample sizes. Other loci showing nominal associations in minorities are shown in Table 5 .
Discussion
Replication of the association of SNPs in the 9p21 region with incident CHD was found in white individuals, as well as generalization of these associations to American Indian individualss but not to black, Hispanic, or Asian/Pacific Islander individuals. Our study size was limited for Hispanic and Asian participants, but previous studies have shown associations of this region with CHD in Pakistani individuals (1851 MI cases and 1903 controls), 37 Han Chinese individuals (510 CHD cases and 557 controls), 38 Japanese and Korean individuals 39, 40 and US Hispanic individuals (82 cases and 108 controls). 3 This locus has been recently shown to disrupt a transcription-factor-binding site involved in the inflammatory response (STAT1), which affects the expression of the CDKN2A-2B genes. 41 Consistent with previous reports, we identified age-and sex-specific effects for the 9p21 locus on CHD risk. The rs10757278 G risk variant showed a larger effect in younger compared with older cohort participants, more evident for individuals age 55 years or younger and in women. Heterogeneity in the estimates for 9p21 in white individuals persisted even after adjusting for multiple risk factors for CHD, but was no longer present in analyses that excluded revascularization procedures from the definition of incident CHD events. Because the use of CHD revascularization procedures (coronary angioplasty or coronary artery bypass graft) may vary in subgroups of individuals because of indication (younger symptomatic individuals and men are more likely to be offered procedures) and to socioeconomic factors (access to care), our results highlight the importance of using strict and homogeneous definition of CHD events when combining data from multiple studies for evaluation of genetic effects. Thus, our results do not support sex-and age-specific effects for 9p21 locus for incident CHD. We were able to replicate multiple other loci in white individuals including MTHFD1L, 16q23.1, 6p24.1, 2q36.3, APOE, ZNF627, CXCL12, and LPL. Most of these loci were initially identified in the Welcome Trust Case Control Consortium (WTCCC). 24 In general, we noticed a modestly greater CHD risk in our prospective analysis compared with the magnitude of association described using a case-control design in previous studies. 24, 28, 42 However, the risk score using these variants showed consistent graded increased CHD risk. In addition, we found significant between-study heterogeneity for the MTHFD1L and CXCL12 loci (online-only Data Supplement Table II) , similar to findings recently described in the case-control meta-analysis of the Coronary ARtery DIsease Genome-wide Replication And MetaAnalysis (CARDIoGRAM) consortium for the MTHFD1L associations. 42 The direction of effect of the remaining SNPs evaluated in white individuals was consistent with those in the discovery studies. Interestingly, 3 loci-CELSR2/SORT1, MIA3 and PCSK9-which have been associated with early-onset MI in whites, 28 did not replicate in our study and in a recently published study of Finland and Sweden individuals. 43 Recent experimental evidence suggests a role of SORT1 product, sortilin 1, in the hepatic metabolism of lipoproteins containing apolipoprotein B. 44 We had over 80% power to detect an effect for this locus in white individuals, assuming effects similar in magnitude to those published. Because our incident cases were first CHD events occurring after age 45 years and the studies that identified these SNPs were cases of early MI compared with controls, our negative findings are not inconsistent with the previously reported associations in white individuals.
None of the SNPs tested were significantly associated with CHD in black participants after adjustments for multiple testing and our samples in Hispanic and Asian participants were limited preventing conclusions. SNPs in the 9p21 region available for this analysis are highly correlated (r 2 Ͼ0.85) in black individuals. However, the genotyped SNPs may not be ideal proxy for functional SNPs in the region for populations of recent African ancestry. In addition, 3 other well-powered SNP associations (rs599839, rs6922269, and rs2943634) were not significant in black participants. Testing additional SNPs at these and other loci may help to elucidate whether LD patterns account for some of the negative findings in black participants.
The strengths of this study are the prospective evaluation of the genetic effect on CHD risk in large populationbased studies and the multiethnic evaluation of CHD loci. Our analyses were limited to SNPs previously identified in individuals of European ancestry, reported by January 2009, when SNP selection was performed for genotyping in PAGE. Therefore, we did not evaluate recently discovered variants, and we were unable to evaluate race-specific 
Ϫ77
The following SNPs (coded allele) were included in the risk score: rs10757278 (G), rs2549513(A), rs499818(A), rs6922269(A), rs429358(C), rs4804611(A), rs501120(T), rs268(G) and rs2943634(C).
HR indicates hazard ratio; CI, confidence interval. variants in these loci that will require fine mapping of the regions. In summary, we identified significant heterogeneity of the 9p21 locus and other loci in individuals of European ancestry in prospective analyses of CHD risk, some of which could be explained by differences in event definition. Overall, some SNP associations replicated in longitudinal analysis of white individuals, but effects were modest; also, none of the SNPs were associated with incident CHD in large sample sizes of black participants. Fine mapping of these regions may help to clarify these negative findings. Funding support for the CALiCo program was provided through the NHGRI PAGE program (U01HG004803). The following studies contributed to this manuscript and are funded by the following agencies: The ARIC study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, and N01-HC-55022. The CARDIA study is supported by the following National Institutes of Health and National Heart, Lung and Blood Institute contracts: N01-HC-95095, N01-HC-48047, N01-HC-48048, N01-HC-48049, N01-HC-48050, N01-HC-45134, N01-HC-05187, and N01-HC-45205. The CHS is supported by contracts N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01-HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, grants U01HL080295 and R01 HL087652 from the National Heart, Lung, and Blood Institute, with additional contribution from the National Institute of Neurological Disorders and Stroke. CHS GWAS DNA handling and genotyping was supported in part by National Center for Research Resources grant M01-RR00425 to the Cedars-Sinai General Clinical Research Center Genotyping core and National Institute of Diabetes and Digestive and Kidney Diseases grant DK063491 to the Southern California Diabetes Endocrinology Research Center. The SHS is supported by NHLBI grants U01 HL65520, U01 HL41642, U01 HL41652, U01 HL41654, and U01 HL65521. The opinions expressed in this article are those of the author(s) and do not necessarily reflect the views of the Indian Health Service.
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